Ozempic, weight reduction medication being distributed inconsistently, examine exhibits

7 Aug

Ozempic, weight reduction medication being distributed inconsistently, examine exhibits


The demand for widespread pharmaceuticals that deal with diabetes, weight problems and coronary heart illness has skyrocketed over the previous few years. New analysis from the College of Southern California confirmed a 442% enhance in prescriptions for semaglutide between January 2021 and December 2023. Semaglutide is the lively ingredient in diabetes medication Ozempic, Rybelsus and Wegovy, a coronary heart illness prevention and weight-loss drug.

Because the record of medical makes use of for these medication continues to develop, sufferers are experiencing extra issue getting their insurers to cowl these prescriptions that may price over $10,000 a yr. In truth, sufferers coated by Medicaid and Medicare characterize a small share of those that’ve had their Ozempic and Wegovy prescriptions crammed.

The USC examine revealed this month in JAMA Well being Discussion board sheds gentle on the disparities Medicaid and Medicare holders face when making an attempt to entry these blockbuster anti-obesity and diabetes medication.